Protons or Photons in Pituitary Neuroendocrine Tumors—That Is Not the Question
Proton techniques spared OARs better than VMAT; however, absolute dose sparing was relatively small, and the clinical value remains uncertain. Nonetheless, the dose reduction, especially for the hippocampi and integral dose, is probably clinically meaningful. We argue that head-CTV should be assessed, as much of the volume receiving dose is located outside the brain. The size and location of the target volume impacted which proton plan was preferable. We conclude that individualized planning is more important than a mere question on protons or photons in PitNET patients.
Authors
- Trine Martens
- Andreas Ottestad
- Magnus Gustavsson
- Taran Paulsen Hellebust (ORCID: https://orcid.org/0000-0002-1540-2040)
- Malin Blomstrand
- Petter Brandal (ORCID: https://orcid.org/0000-0003-0259-495X)
- Corina S. Rueegg (ORCID: https://orcid.org/0000-0003-3720-4659)
- Hanne Blakstad (ORCID: https://orcid.org/0000-0003-3672-9090)
- Christina Ramberg
- Liv Cathrine Heggebø (ORCID: https://orcid.org/0000-0003-2891-9636)
- Maziar Hervani
- T. W. Henry (ORCID: https://orcid.org/0000-0001-9039-4979)
- Lars Fredrik Fjæra (ORCID: https://orcid.org/0000-0001-6521-506X)
- Frank Leonel Bello Garrote
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Sahlgrenska University Hospital (SE)
- University of South-Eastern Norway (NO)
- University of Gothenburg (SE)
Publication Details
- Journal
- International Journal of Particle Therapy
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.ijpt.2025.101194
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00